Effect of HMP on Diabetic Microangiopaemia in T2DM

• Status: Not yet recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The study mainly investigates the therapeutic effect of Heart-Protecting Musk Pill (HMP) on patients with diabetic microangiopathy. According to the indicators of diabetic nephropathy (DN), diabetic retinopathy (DR), oxidative stress and inflammatory factor in patients with diabetic microvascular disease after using HMP, we aim to evaluate the effect of HMP on diabetic microangiopathy, oxidative stress and inflammation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Affiliated Hospital of Nantong University
• Treatments: Calcium Dobesilate; Valsartan

Criteria

Inclusion Criteria:

( - )Diabetes mellitus was diagnosed based on the 1999 World Health Organization diagnostic criteria.

( - )for Valsartan and Calcium Dobesilate. ( - )All participants signed an informed consent form in the study.

Exclusion Criteria:

( - )Impaired heart, liver or kidney function, malignant tumors, and active infection ( - )type 1 diabetes mellitus or secondary diabetes ( - )mental illness or intellectual disability ( - )acute diabetic complications or macrovascular complications.